Study wrapper · #864
Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.
Alsakran WA, Alkhaldi HM, Magliyah MS BMC ophthalmology. 2026.
DOI: 10.1186/s12886-026-05122-yPubMed: 42432542
Editor's note
A single case report describing bilateral non-arteritic anterior ischemic optic neuropathy with branch retinal artery occlusion emerging after eleven months of semaglutide and partly recovering after discontinuation. It adds to an active safety conversation about GLP-1 agonists and NA-AION, and the temporal dechallenge pattern is suggestive, but one patient cannot establish causation. A relevant safety data point that belongs alongside the larger pharmacovigilance signal rather than standing on its own.
Plain-language abstract
In one man, vision loss from optic-nerve and retinal-artery problems appeared after 11 months on semaglutide and partly recovered once the drug was stopped.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026